openPR Logo
Press release

Hope for Rapid, Non-Invasive Endometriosis Diagnosis

03-14-2025 04:38 PM CET | Health & Medicine

Press release from: ABNewswire

New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to deliver results with unprecedented speed and accuracy, slashing the current 5.3-year average diagnostic delay in Canada to less than an hour. Jayme Doll's reporting for Global News is available at: https://globalnews.ca/news/11074941/lets-talk-about-it-period/

Endometriosis, a condition affecting approximately 1 in 10 women, has long been challenging to diagnose, often requiring invasive procedures and prolonged wait times. The ENDOSURE test, however, offers a paradigm shift in endometriosis detection with accurate, rapid, objective results obtained non-invasively.

Despite its potential, the ENDOSURE test remains largely inaccessible to patients, pending recognition and adoption by the healthcare system.

"It's just existential dread," shares Rose Plican, a 19-year-old endometriosis patient. "Wrapped in a blanket, waiting and wishing away the pain. I just physically can't get out of bed. I can't move. So, it's stopped me in a lot of ways from sort of just living." Rose's story echoes the struggles of countless women facing years-long waitlists for specialists and invasive diagnostic procedures.

Her mother, Carolyn Plican, a patient advocate, emphasizes the psychological impact of a diagnosis: "Suddenly when you're diagnosed, you know it's not in your head. It gives you permission to find better strategies to manage pain and get on a wait list for a laparoscopy to have it excised if it's affecting you really badly."

Dr. Mary Ellen Haggerty supports the ENDOSURE test, stating, "It's a decision help. I think it's really good to make those sorts of diagnosis early. This confirms the diagnosis without being an invasive procedure."

The ball is now in the court of healthcare decision-makers. Will they recognize the value of using the ENDOSURE test for early diagnosis, which has been authorized for sale by Health Canada since 2021, as a significant step towards helping women in debilitating pain? As the medical community debates the role of this new technology, advocates like Carolyn Plican continue to advocate for better access to the ENDOSURE test with its potential to revolutionize endometriosis care by:

* Reducing diagnostic delays
* Minimizing invasive procedures
* Improving patient quality of life
* Potentially lowering healthcare costs long-term

If you are advocating for yourself or someone you love to access earlier diagnostic testing for endometriosis because of pelvic pain, period pain, or infertility, please join the ENDOSURE waitlist at EndoDiagnosis [https://endodiagnosis.com/hope-for-rapid-non-invasive-endometriosis-diagnosis/].

For more information about the ENDOSURE test please contact:

Carolyn Plican

https://endodiagnosis.com/

1-833-439-3636

at hello@endodiagnosis.com [mailto:hello@endodiagnosis.com]

EndoDiagnosis, Inc

EndoDiagnosis, Inc was spearheaded by a Canadian team of healthcare professions to bring rapid diagnostic tools and other adjuncts that expedite endometriosis care. The ENDOSURE Test is a non-invasive, 99% accurate diagnostic test for endometriosis, providing instant results in 30-minutes. ENDOSURE provides clinical evidence for practitioners who suspect endometriosis in their patients with dysmenorrhea and/or chronic pelvic pain, infertility & miscarriage or for pre pregnancy screening

EndoDiagnosis, Inc became the Manufacturer's Agent for ENDOSURE in Canada in December 2024. ENDOSURE has been authorized for sale by Health Canada since 2021 for the indication of endometriosis.

Media Contact
Company Name: EndoDiagnosis, Inc
Contact Person: Carolyn Plican
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hope-for-rapid-noninvasive-endometriosis-diagnosis]
Phone: 780-292-4198, 833-439-3636
Country: Canada
Website: https://endodiagnosis.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hope for Rapid, Non-Invasive Endometriosis Diagnosis here

News-ID: 3916195 • Views:

More Releases from ABNewswire

Best AI Headshot Generator for 2026: How to Choose the Right Tool
Best AI Headshot Generator for 2026: How to Choose the Right Tool
A practical buyer's guide to choosing an AI headshot generator in 2026. Compares Magic Hour, Nano Banana (Gemini), HeadshotPro, and Canva across image realism, consistency, speed, reliability, restrictions, and cost clarity, with "best for" recommendations across common workflows. AI headshot generators vary widely in what they optimize for. Some focus on photorealism and facial accuracy, others prioritize speed and ease of use, while some are designed for teams and brand consistency.
$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
Small-cap stocks trading near the $5 level are back on investor watchlists as volatility and headline-driven momentum return to the market. ENDRA Life Sciences (NASDAQ: NDRA), ImmunityBio (NASDAQ: IBRX), Movano Inc. (NASDAQ: MOVE), and Rivalry Corp. (TSXV: RVLY) are all seeing renewed interest, driven by a mix of clinical progress, revenue developments, compliance milestones, and sector-specific trends. ENDRA Life Sciences (NASDAQ: NDRA) is a medical technology company developing advanced ultrasound solutions
$2 Stocks: DRCT, RDZN, KUST, SNYR, TOON Gaining Attention Watch Now!
$2 Stocks: DRCT, RDZN, KUST, SNYR, TOON Gaining Attention Watch Now!
Lower-priced equities trading around the $2 level are drawing renewed interest as investors search for volatility and near-term catalysts. Direct Digital Holdings (NASDAQ: DRCT), Roadzen Inc. (NASDAQ: RDZN), Kustom Entertainment (NASDAQ: KUST), Synergy CHC Corp. (NASDAQ: SNYR) and Kartoon Studios (NYSE: TOON) are all seeing increased attention tied to corporate actions, strategic shifts, and growth initiatives that could influence performance into 2026. Direct Digital Holdings (NASDAQ: DRCT) has continued to attract
Chronic Urticaria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Chronic Urticaria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the …
DelveInsight's "Chronic Urticaria Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Dive into DelveInsight's comprehensive report

All 5 Releases


More Releases for ENDOSURE

ENDOSURE Tier 1 Endometriosis Testing Now Available in North America for First T …
Calgary, AB, Canada - June 13, 2025 - Marda Loop Wellness today announces it will become North America's first primary care clinic to offer the groundbreaking ENDOSURE test for endometriosis detection, beginning June 16, 2025. This innovative, non-invasive diagnostic tool delivers results in 30 minutes with over 99% accuracy, addressing a critical gap in women's healthcare where traditional diagnosis typically takes 8.6 years globally. "The introduction of ENDOSURE testing represents a